Adiponectin gene therapy ameliorates high-fat, high-sucrose diet-induced metabolic perturbations in mice

• Published in: Nutrition & diabetes Vol. 2; no. 9; p. e45
• Main Authors: Kandasamy, A D, Sung, M M, Boisvenue, J J, Barr, A J, Dyck, J R B
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 10-09-2012; Nature Publishing Group
• Subjects: 631/154/51/201; 631/80/86/2367; 692/699/1702/393; 692/699/2743/137/773; Clinical Nutrition; Diabetes; Epidemiology; Internal Medicine; Medicine; Medicine & Public Health; Metabolic Diseases; Original; original-article; gene delivery; adiponectin; insulin signaling; electroporation; obesity; high fat diet
• ISSN: 2044-4052; 2044-4052
• DOI: 10.1038/nutd.2012.18

Background and Design:
Adiponectin is an adipokine secreted primarily from adipose tissue that can influence circulating plasma glucose and lipid levels through multiple mechanisms involving a variety of organs. In humans, reduced plasma adiponectin levels induced by obesity are associated with insulin resistance and type 2 diabetes, suggesting that low adiponectin levels may contribute the pathogenesis of obesity-related insulin resistance.
Methods and Results:
The objective of the present study was to investigate whether gene therapy designed to elevate circulating adiponectin levels is a viable strategy for ameliorating insulin resistance in mice fed a high-fat, high-sucrose (HFHS) diet. Electroporation-mediated gene transfer of mouse adiponectin plasmid DNA into gastrocnemius muscle resulted in elevated serum levels of globular and high-molecular weight adiponectin compared with control mice treated with empty plasmid. In comparison to HFHS-fed mice receiving empty plasmid, mice receiving adiponectin gene therapy displayed significantly decreased weight gain following 13 weeks of HFHS diet associated with reduced fat accumulation, and exhibited increased oxygen consumption and locomotor activity as measured by indirect calorimetry, suggesting increased energy expenditure in these mice. Consistent with improved whole-body metabolism, mice receiving adiponectin gene therapy also had lower blood glucose and insulin levels, improved glucose tolerance and reduced hepatic gluconeogenesis compared with control mice. Furthermore, immunoblot analysis of livers from mice receiving adiponectin gene therapy showed an increase in insulin-stimulated phosphorylation of insulin signaling proteins.
Conclusion:
Based on these data, we conclude that adiponectin gene therapy ameliorates the metabolic abnormalities caused by feeding mice a HFHS diet and may be a potential therapeutic strategy to improve obesity-mediated impairments in insulin sensitivity.